BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.70 Consensus Target Price from Brokerages

Key Points

• BioCryst Pharmaceuticals has received a consensus rating of "Moderate Buy" from ten analyst firms, with one hold rating and nine buy ratings.
• The company's stock price target has seen various adjustments, with Wedbush raising it from $16.00 to $18.00 recently.
• BioCryst reported a record revenue of $163.35 million for the last quarter, significantly exceeding analyst expectations of $149.59 million.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $16.70.

A number of equities analysts recently weighed in on the company. Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Bank of America lifted their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, July 1st. Wedbush boosted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of BCRX. Osaic Holdings Inc. boosted its holdings in BioCryst Pharmaceuticals by 10.1% in the second quarter. Osaic Holdings Inc. now owns 48,611 shares of the biotechnology company's stock worth $436,000 after purchasing an additional 4,466 shares in the last quarter. Headlands Technologies LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1,208.9% during the 2nd quarter. Headlands Technologies LLC now owns 55,221 shares of the biotechnology company's stock worth $495,000 after acquiring an additional 51,002 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in shares of BioCryst Pharmaceuticals by 20.5% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 60,906 shares of the biotechnology company's stock valued at $546,000 after acquiring an additional 10,361 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of BioCryst Pharmaceuticals by 213.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 21,758 shares of the biotechnology company's stock valued at $195,000 after acquiring an additional 14,822 shares during the last quarter. Finally, Exome Asset Management LLC raised its stake in shares of BioCryst Pharmaceuticals by 185.3% in the 2nd quarter. Exome Asset Management LLC now owns 172,883 shares of the biotechnology company's stock valued at $1,549,000 after acquiring an additional 112,283 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX traded down $0.07 during trading on Friday, hitting $8.01. The company had a trading volume of 2,604,250 shares, compared to its average volume of 2,184,051. BioCryst Pharmaceuticals has a 52 week low of $6.01 and a 52 week high of $11.31. The business's 50-day moving average is $8.47 and its 200 day moving average is $8.73. The company has a market cap of $1.68 billion, a P/E ratio of -44.50, a PEG ratio of 1.84 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. The business's revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.